Kent Payne Bio

Kent Payne, Ph.D, is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. Kent combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across biotechnology and pharmaceutical market segments from discovery through cGMP commercial manufacturing. In addition to the U.S., he has successfully led the geographic expansion of businesses into Asia, South America and Europe. He serves as a board member for Goodwin Biotechnologies. He held prior Board and Advisory roles at Life Science Institute, Technophar, Qualicaps, and PDS Biotechnology (PDSB). Previously, Kent was CEO at Aliri Bioanalysis, CEO at BioDuro, CEO at Socorro Pharmaceuticals, (a generic pharmaceutical company); President Americas at Qualicaps; Vice President/General Manager at Catalent Pharma Solutions in addition to posts at Novartis; Monsanto and G.D. Searle.